Abbott Laboratories
Corporate Bias Rating
Expand Summary
Risk Level:
Summary:
Abbott Laboratories is High Risk. The company yields to political activism in shaping corporate governance, potentially alienating consumers, dividing employees, and harming shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. Abbott Laboratories embraces corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues. This approach fails to safeguard free exercise, free speech, and free enterprise.
View Full Corporate Bias Ratings ReportBoard Bias
Expand Summary
CEO of Abbott Laboratories
Robert B. Ford
Summary:
Headquartered in Abbott Park, Illinois, Abbott Laboratories is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. Robert B. Ford and Robert B. Ford serve as CEO/President and Chairman, respectively, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $361,095 to Republican causes and $77,875 to Democratic causes. Under their tenure, Abbott Laboratories currently holds a 'High Risk' risk rating.
View Full Board Bias ReportPolitical Contributions of Leadership:
$361,095
$77,875
Republican
Democrat
China Risk Database
Expand Summary
Total Estimated Sanctions (3-year Avg.)
$528,587,476
Average Annual Revenue
Global
$36,279,666,667
China Revenue
5.89%
$2,136,333,333
Annual Average of Total Assets
Global
$71,386,333,333
China Assets
5.99%
$4,277,723,590
Shareholder Proposals
Expand Summary
| Date | ESG Category | Proponent | Summary of Resolution | Mgmt Rec | Total Vote % in Favor |
|---|---|---|---|---|---|
| 4/28/23 | Governance | Kenneth Steiner | Request that the Board Chairman be an Independent Director | Against | 30.50% |
| 4/28/23 | Governance | The Province of Saint Joseph of the Capuchin Order and Proxy Impact | Prepare Annual Report Disclosing Policies, Procedures, and Expenditures. | Against | 23.00% |
| 4/28/23 | Governance | The Shareholder Association for Research & Education | Financial Performance Metric for Senior Level Executives Include Legal and Compliance Costs | Against | 14.40% |
| 4/28/23 | Governance | John Chevedden | Lower Ownership Threshold for Calling Special Meetings | Against | 4.30% |
| 4/29/22 | Governance | NYC Comptroller's Office | Adopt Policy on 10b5-1 Trading Plans | Against | 48.76% |
| 4/29/22 | Governance | John Chevedden | Reduce Ownership Threshold for Shareholders to Call Special Meeting | Against | 47.15% |
| 4/29/22 | Social | Unitarian Universalist Assoc. | Report on Lobbying Payments and Policy | Against | 34.52% |
| 4/29/22 | Governance | Kenneth Steiner | Require Independent Board Chair | Against | 27.75% |
| 4/29/22 | Social | The Shareholder Commons | Report on Public Health Costs of Antimicrobial Resistance | Against | 11.51% |